Personalized Vaccination of Tumor‐Derived Antigens and STING Agonists for Specific Cancer Immunotherapy
Advanced Materials · 2026
DOI: 10.1002/adma.202420325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Ning Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, and the School of Biome…. Hauptthemen laut MEDLINE: Immunotherapy, Cancer Vaccines, Antigens, Neoplasm, Membrane Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Center for International Cooperation and Disciplinary Innovation, Natural Science Foundation of Shandong Province of China.
Abstract (Originalsprache)
Personalized vaccines have shown their promise in cancer immunotherapy, while screening of personalized antigens remains challenging. Herein, a personalized immunotherapy strategy to treat tumors by its own mechanism is reported, which is achieved through the hydrogel‐integrated delivery of tumor‐derived antigens and STING signaling activation. Self‐assembled nanoparticles composed of gallic acid, manganese ions, and mitoxantrone are prepared to induce immunogenic cell death of tumor cells in vitro to release damage‐associated molecular patterns and autologous antigens. Sodium alginate integrated with the released antigens and STING agonists (i.e., MSA‐2) can be instantaneously cross‐linked with endogenous calcium ions in vivo to form hydrogels upon subcutaneous injection. The hydrogels allow for the controlled release of autologous tumor antigens and agonists to activate specific anti‐tumor immune responses via promotion of the maturation of dendritic cells and elicitation of tumor infiltration of cytotoxic T lymphocytes. As a result, the in‐situ formation of hydrogel‐based vaccines can prevent homologous tumor progression and inhibit metastatic tumor growth. This work outlines a straightforward and generalized strategy for personalized vaccination to enhance cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, and the School of Biomedical Engineering, Shandong University, Jinan, Shandong, 250100, China.
- Shandong Key Laboratory of Oral Tissue Regeneration, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
- Shandong Key Laboratory of Targeted Drug Delivery and Advanced Pharmaceutics, Shandong University, Jinan, Shandong, 250100, China.
ORCID-Profile: Jiwei Cui
Förderung
- National Natural Science Foundation of China
- Center for International Cooperation and Disciplinary Innovation
- Natural Science Foundation of Shandong Province of China
Zitieren
APA
Wang, N., Zhang, X., Gao, Z., Jiang, X., Li, J., Hao, J., & Cui, J. (2026). Personalized Vaccination of Tumor‐Derived Antigens and STING Agonists for Specific Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202420325
Vancouver
Wang N, Zhang X, Gao Z, Jiang X, Li J, Hao J, et al. Personalized Vaccination of Tumor‐Derived Antigens and STING Agonists for Specific Cancer Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.202420325
BibTeX
@article{Wang2026,
author = {Wang, Ning and Zhang, Xiaohui and Gao, Zhiliang and Jiang, Xinyi and Li, Jianhua and Hao, Jingcheng and Cui, Jiwei},
title = {Personalized Vaccination of Tumor‐Derived Antigens and STING Agonists for Specific Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202420325}
}
EUVIMED